Ascendis Pharma Surges 3%: A Potential Indication of Further Gains?

Ascendis Pharma (ASND) shares surged 3% due to commercial performance of its marketed drugs, Skytrofa and Yorvipath, for growth hormone deficiency and hypoparathyroidism, respectively. Q4 revenues are expected to be €53 million and €187 million, respectively. The company is also evaluating these drugs for label expansion into other indications. Earnings and revenue growth expectations give a good sense of potential strength in the stock, but negative earnings estimate revisions don't usually translate into price appreciation. ASND carries a Zacks Rank #3 (Hold).